Biomarkers for Immune Checkpoint Inhibitors in Melanoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2018 Aug 4

PMID 30073150

Citations 34

Authors

Shigehisa Kitano

Takayuki Nakayama

Makiko Yamashita

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors have now become a standard therapy for malignant melanoma. However, as immunotherapies are effective in only a limited number of patients, biomarker development remains one of the most important clinical challenges. Biomarkers predicting clinical benefit facilitate appropriate selection of individualized treatments for patients and maximize clinical benefits. Many biomarkers derived from tumors and peripheral blood components have recently been reported, mainly in retrospective settings. This review summarizes the recent findings of biomarker studies for predicting the clinical benefits of immunotherapies in melanoma patients. Taking into account the complex interactions between the immune system and various cancers, it would be difficult for only one biomarker to predict clinical benefits in all patients. Many efforts to discover candidate biomarkers are currently ongoing. In the future, verification, by means of a prospective study, may allow some of these candidates to be combined into a scoring system based on bioinformatics technology.

Citing Articles

Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment.

Sosa Cuevas E, Mouret S, Vayssiere G, Kerboua S, Girard P, Molens J Front Immunol. 2024; 15:1507938.

PMID: 39687620 PMC: 11646980. DOI: 10.3389/fimmu.2024.1507938.

Impact of Physical Exercise on Melanoma Hallmarks: Current Status of Preclinical and Clinical Research.

Ceci C, Garcia-Chico C, Atzori M, Lacal P, Lista S, Santos-Lozano A J Cancer. 2024; 15(1):1-19.

PMID: 38164270 PMC: 10751671. DOI: 10.7150/jca.88559.

Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1.

Janka E, Vanyai B, Szabo I, Toka-Farkas T, Varvolgyi T, Kapitany A Front Oncol. 2023; 13:1237643.

PMID: 37664072 PMC: 10472446. DOI: 10.3389/fonc.2023.1237643.

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.

Khan M, Du K, Ai M, Wang B, Lin J, Ren A Front Immunol. 2023; 14:1060308.

PMID: 36949944 PMC: 10027008. DOI: 10.3389/fimmu.2023.1060308.

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma.

Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A Front Oncol. 2023; 12:966527.

PMID: 36698400 PMC: 9869613. DOI: 10.3389/fonc.2022.966527.

References

Jandus C, Bioley G, Speiser D, Romero P . Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother. 2008; 57(12):1795-805. PMC: 11030612. DOI: 10.1007/s00262-008-0507-4. View

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

Gibney G, Kudchadkar R, DeConti R, Thebeau M, Czupryn M, Tetteh L . Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2014; 21(4):712-20. PMC: 4620684. DOI: 10.1158/1078-0432.CCR-14-2468. View

Tietze J, Angelova D, Heppt M, Reinholz M, Murphy W, Spannagl M . The proportion of circulating CD45ROCD8 memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. Eur J Cancer. 2017; 75:268-279. DOI: 10.1016/j.ejca.2016.12.031. View

Richards J, Mehta N, Ramming K, Skosey P . Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992; 10(8):1338-43. DOI: 10.1200/JCO.1992.10.8.1338. View

Jacquelot N, Roberti M, Enot D, Rusakiewicz S, Ternes N, Jegou S . Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017; 8(1):592. PMC: 5605517. DOI: 10.1038/s41467-017-00608-2. View

Hui E, Cheung J, Zhu J, Su X, Taylor M, Wallweber H . T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017; 355(6332):1428-1433. PMC: 6286077. DOI: 10.1126/science.aaf1292. View

Weber J, Gibney G, Kudchadkar R, Yu B, Cheng P, Martinez A . Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res. 2016; 4(4):345-53. PMC: 4818672. DOI: 10.1158/2326-6066.CIR-15-0193. View

10.

Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K . Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget. 2016; 7(47):77404-77415. PMC: 5363594. DOI: 10.18632/oncotarget.12677. View

11.

Parker K, Beury D, Ostrand-Rosenberg S . Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res. 2015; 128:95-139. PMC: 4662416. DOI: 10.1016/bs.acr.2015.04.002. View

12.

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View

13.

Tarhini A, Edington H, Butterfield L, Lin Y, Shuai Y, Tawbi H . Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705. PMC: 3912016. DOI: 10.1371/journal.pone.0087705. View

14.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

15.

Retseck J, VanderWeele R, Lin H, Lin Y, Butterfield L, Tarhini A . Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer. 2016; 4:38. PMC: 4915044. DOI: 10.1186/s40425-016-0141-1. View

16.

Kitano S, Postow M, Ziegler C, Kuk D, Panageas K, Cortez C . Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res. 2014; 2(8):812-21. PMC: 4125466. DOI: 10.1158/2326-6066.CIR-14-0013. View

17.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

18.

Peng W, Chen J, Liu C, Malu S, Creasy C, Tetzlaff M . Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2015; 6(2):202-16. PMC: 4744499. DOI: 10.1158/2159-8290.CD-15-0283. View

19.

Kim H, Lee H, Kim S, Jin H, Bae J, Choi H . Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling. Sci Rep. 2017; 7(1):8864. PMC: 5562697. DOI: 10.1038/s41598-017-08433-9. View

20.

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View